OCUL Company Profile and Key Details

Q: Who are the executives of OCUL?

Mr. Scott CorningSenior Vice President of CommercialMs. Tracy SmithVice President of HRDr. Peter K. Jarrett Ph.D.Chief Scientific OfficerDr. Rabia Gurses Ozden M.D.Chief Medical OfficerMr. Philip C. StrassburgerGen. CounselDr. Karen-Leigh Edwards M.B.A., Ph.D.Senior Vice President of Technical OperationsMr. William H. Ransone IIVice President of Global Sales & MarketingMr. Christopher G. WhiteChief Bus. OfficerMr. Steve MeyersSenior Vice President of CommercialMr. Philip C. Strassburger Esq.Gen. CounselMr. Antony MattessichPres, Chief Executive Officer & DirectorMr. Donald Notman Jr.Chief Financial Officer

NASDAQ : OCUL

Ocular Therapeutix

$9.88

-0.32-3.14%

At Close 4:00 PM

72.03

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ocular Therapeutix, Inc. (OCUL) stock declined over -3.14%, trading at $9.88 on NASDAQ, down from the previous close of $10.20. The stock opened at $10.15, fluctuating between $9.76 and $10.19 in the recent session.

Stock Snapshot

10.2

Prev. Close

2.16B

Market Cap

9.76

Day Low

-6.77

P/E Ratio

-1.46

EPS (TTM)

-0.84

Cash Flow per Share

10.15

Open

218.96M

Number of Shares

10.185

Day High

83.47%

Free Float in %

1.08

Book Value

1.4M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	10.14	10.19	9.76	9.88	1.44M
Jul 10, 2026	10.51	10.53	10.07	10.20	1.88M
Jul 09, 2026	10.16	10.94	10.15	10.54	2.43M
Jul 08, 2026	10.22	10.43	9.91	10.27	3.2M
Jul 07, 2026	9.80	10.51	9.64	10.33	2.87M
Jul 06, 2026	9.54	9.83	9.43	9.66	2.41M
Jul 02, 2026	9.56	9.74	9.41	9.64	1.83M
Jul 01, 2026	9.91	10.05	9.44	9.47	2.18M
Jun 30, 2026	9.98	10.19	9.80	9.82	2.45M
Jun 29, 2026	9.80	9.98	9.65	9.90	2.06M
Jun 26, 2026	9.78	10.09	9.61	9.84	8.12M
Jun 25, 2026	9.79	10.24	9.71	9.76	2.24M
Jun 24, 2026	10.17	10.39	9.74	9.85	2.76M
Jun 23, 2026	9.83	10.62	9.80	10.12	2.76M
Jun 22, 2026	9.51	10.14	9.41	9.97	5.16M
Jun 18, 2026	10.00	10.39	9.37	9.43	6.11M
Jun 17, 2026	9.19	9.74	8.62	9.64	7.39M
Jun 16, 2026	8.99	9.11	8.67	8.94	2.33M
Jun 15, 2026	8.94	9.26	8.76	8.99	2.47M
Jun 12, 2026	8.65	8.96	8.62	8.94	2.69M

Contact Details

Bedford, MA 01730

United States

https://www.ocutx.com 781 357 4000

About Company

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

Ocular Therapeutix, Inc. (NASDAQ:OCUL) closed at $9.88 USD, losing -$0.32 (-3.14%) from the previous close of $10.20. The stock is currently mid-range between its 52-week high and low $6.23 and $16.44. With a market capitalization of about $2.16 billion, Ocular Therapeutix, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.88). Key stats such as the average daily volume over the past year has been around 2.92 million shares, volume is running light vs its 52-week average. Headquartered in Bedford, MA, Ocular Therapeutix, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pravin U. Dugel, the company employs approximately 325 people and listed since July 25, 2014. Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments.

Technical Performance

OCUL has shown mixed momentum, gaining 7.11% over the past week and -3.29% over the past quarter, though year-to-date performance is down -5.68%. Short-term trend indicators are bullishly aligned (SMA20 10.19%, SMA50 -9.4%, SMA200 -12.61%). The stock’s 14-day RSI is 52.93 (neutral), while the ATR of 0.77 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -41.67% below its high and over 65.77% above its low. Average 10-day trading volume of 2.37 million shares is below the 3-month average of 2.90 million, indicating normal recent market interest.

Valuation Metrics

Ocular Therapeutix, Inc. trades at a P/E ratio of -6.72, slightly below the S&P 500 average, with a price-to-sales ratio of 41.31 and a price-to-book ratio of 3.78 trading at moderately above to book value. The P/FCF stands at -8.92, also above market averages.

Dividend & Fair Value

Ocular Therapeutix, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.83. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Ocular Therapeutix, Inc. generated EPS of -$1.44 over the past year. Five-year average earnings growth is 11.13%. Wall Street analysts project EPS growth of 11.99% annually over the next five years. The latest quarter delivered EPS of -$0.41. The next quarter is forecast at -$0.32. Next year's EPS is expected at -$0.14. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 18 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $31.00 to $15.00. The high target offers 213.77% upside. The low target suggests 51.82% downside. The mean target is $22.42. This offers 126.92% upside. Ocular Therapeutix, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 28.12%. The prior quarter beat by -12.12%. Over the last six quarters, Apple has recorded several small beats. These include 20.83% in March 03, 2025.

Shareholding & Insider Activity

Ocular Therapeutix, Inc. has 174.00 million shares outstanding. The public float is 145.32 million shares, elevated short interest at 7.45% of float. This equals 12.83 million shares. The short ratio is 6.08 days. Institutional investors hold 93.96% of the float. Insiders own 3.35%. SUMMER ROAD LLC holds 8.59 million shares, Opaleye Management Inc. has 4.92 million shares and Dugel Pravin has 2.60 million shares. Over the past six months, insider transactions show net selling. They sold 241.05 thousand shares across 16 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Ocular Therapeutix generated $58.44M in revenue, or $0.68 per share. Gross margin was 90.96%, operating margin -140.96%, and net profit margin -138.14%. Returns are negative, with ROA at -32.03% and ROE at -88.59%.
On valuation metrics, Ocular Therapeutix trades at a P/E of -6.72, P/S of 41.31 and P/B of 3.78. The current ratio is 14.81 and quick ratio is 14.73. Operationally, the company’s inventory turnover is 1.78 and cash conversion cycle is -64.96 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.14, supported by a cash flow-to-debt ratio of -2.85.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Ocular Therapeutix posted revenue of $58.44M, down slightly from $51.49M in the prior quarter. Gross profit was $53.16M (margin 90.96%). Operating income was - $82.38M (margin -141.0%). Net income was- $80.74M (EPS - $1.01).
The company ended the quarter with $195.96M in cash and short-term investments, a total debt of $83.39M, and net debt of - $112.57M. Total assets were $252.06M, with equity of $91.13M. Financials further reflected weakness, with operating cash flow of - $70.23M, free cash flow of - $76.32M, and capital expenditures of - $6.09M.

Price Forecast & Outlook

Our AI price prediction model suggests that Ocular Therapeutix, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.79%, with price expected at $10.65 by July 27, 2026, within a range of $10.24 to $11.04 3-Month Outlook: Projected fall of -13.87%, reaching $8.51 by October 08, 2026, with a range of $8.22 to $8.85. 1-Year Outlook: Projected gain of 114.47%, with price at $21.19 by July 13, 2027, within a range of $5.71 to $34.71.

Key Takeaways

Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares are flat -5.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ocular Therapeutix, Inc. trading at a premium to the broader market with a P/E of -6.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.14, suggesting 83.6% upside. Our AI forecast model points to short-term strength (7.79% over two weeks), a medium-term fall (-13.87% over three months), and a longer-term gain (114.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Ocular Therapeutix, Inc. (OCUL) stock price?

Ocular Therapeutix, Inc. (NASDAQ: OCUL) stock price is $9.88 in the last trading session. During the trading session, OCUL stock reached the peak price of $10.19 while $9.76 was the lowest point it dropped to. The percentage change in OCUL stock occurred in the recent session was -3.14% while the dollar amount for the price change in OCUL stock was - $0.32.

OCUL's industry and sector of operation?

The NASDAQ listed OCUL is part of Biotechnology industry that operates in the broader Healthcare sector. Ocular Therapeutix, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OCUL?

Mr. Scott Corning
Senior Vice President of Commercial
Ms. Tracy Smith
Vice President of HR
Dr. Peter K. Jarrett Ph.D.
Chief Scientific Officer
Dr. Rabia Gurses Ozden M.D.
Chief Medical Officer
Mr. Philip C. Strassburger
Gen. Counsel
Dr. Karen-Leigh Edwards M.B.A., Ph.D.
Senior Vice President of Technical Operations
Mr. William H. Ransone II
Vice President of Global Sales & Marketing
Mr. Christopher G. White
Chief Bus. Officer
Mr. Steve Meyers
Senior Vice President of Commercial
Mr. Philip C. Strassburger Esq.
Gen. Counsel
Mr. Antony Mattessich
Pres, Chief Executive Officer & Director
Mr. Donald Notman Jr.
Chief Financial Officer

How OCUL did perform over past 52-week?

OCUL's closing price is 58.59% higher than its 52-week low of $6.23 where as its distance from 52-week high of $16.44 is -39.9%.

How many employees does OCUL have?

Number of OCUL employees currently stands at 274.

Link for OCUL official website?

Official Website of OCUL is: https://www.ocutx.com

How do I contact OCUL?

OCUL could be contacted at phone 781 357 4000 and can also be accessed through its website. OCUL operates from 24 Crosby Drive, Bedford, MA 01730, United States.

How many shares of OCUL are traded daily?

OCUL stock volume for the day was 1.4M shares. The average number of OCUL shares traded daily for last 3 months was 2.92M.

What is the market cap of OCUL currently?

The market value of OCUL currently stands at $2.16B with its latest stock price at $9.88 and 218.96M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	274
Beta	0.88
Sales or Revenue	$58.44M
5Y Sales Change%	13.022%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

OCUL Company Profile and Key Details

Ocular Therapeutix

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook